Enhancing antibody efficacy in plants via targeted manipulation of dolichol biosynthesis

点击翻译按钮获取中文摘要

PlantForm Corporation is a Canadian company that specializes in turning plants into versatile 'bioreactors' for the production of therapeutic proteins used in the treatment of HIV/AIDS, breast and other forms of cancer. Compared to current animal systems that are used to produce protein based therapeutics, PlantForm's plant-based production system lowers the manufacturing costs considerably. Any advancement in PlantForm's mAbs production efficiency will not only give them a competitive edge in this billion dollar biopharmaceutical market, but lower production costs translate into lower treatment costs for the thousands of Canadians who are affected by such diseases. The objective of this research project is to enhance PlantForm's bioproduction platform by incorporating technology that has recently been developed by Dr. Tariq Akhtar at the University of Guelph. Specifically, this research project aims to improve the yield of functional monoclonal antibodies that can be produced in plants.